OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Duvic on Importance of Classifying T-Cell Lymphomas

November 4th 2016

Madeleine Duvic, MD, professor of Medicine and Dermatology, Blanche Bender Professorship in Cancer Research, director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of classifying T-cell lymphomas and new targets in development. Duvic shared this insight during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma

November 4th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.

Dr. Alice T. Shaw on Ceritinib for Frontline ALK+ NSCLC With Brain Metastases

November 4th 2016

Alice T. Shaw, MD, PhD, thoracic oncologist at the Massachusetts General Hospital Cancer Center, discusses ceritinib in newly diagnosed patients with ALK-positive non-small cell lung cancer (NSCLC) and brain metastases.

Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCC

November 3rd 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.

Dr. David L. Rimm on the Continued Role for PD-L1 Testing in NSCLC

November 3rd 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the continued role for PD-L1 testing to predict response with checkpoint inhibitors in non–small cell lung cancer (NSCLC).

Jena D. French on Anti-PD-1/Lenvatinib Combo in Differentiated Thyroid Cancer

November 3rd 2016

Jena D. French, PhD, instructor of medicine, division of endocrinology, metabolism and diabetes, Anschutz Medical Campus, University of Colorado, discusses the potential for immunotherapy combinations with lenvatinib in differentiated thyroid cancer.

Dr. Pal on Sequencing Challenges for the Treatment of Patients With RCC

November 3rd 2016

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Garcia-Manero on Curing Patients With MDS and AML

November 2nd 2016

Guillermo Garcia-Manero, MD, professor of Medicine, chief, Section of Myelodysplastic Syndromes, in the Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of curing patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Garcia-Manero explained this reasoning in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.

Dr. DeCamp on Platforms of Surgical Management in Lung Cancer

November 2nd 2016

Malcolm McAvoy DeCamp, Jr, MD, chief of Thoracic Surgery in the Department of Surgery, Northwestern University Feinberg School of Medicine, discusses different platforms of surgical management in the treatment of patients with lung cancer.

Dr. Schoenfeld on Preventing Immune Suppression With Radiation and Immunotherapy Combos

November 2nd 2016

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses challenges with immune suppression with radiation and immunotherapy combinations.

Dr. Elizabeth H. Baldini on Systemic Therapy for Sarcoma

November 2nd 2016

Elizabeth H. Baldini, MD, MPH, director, radiation oncology, center for sarcoma and bone oncology, associate professor of radiation oncology, Harvard Medical School, discusses sarcoma

Dr. Ferrajoli on Remaining Challenges in Treatment of CLL

November 2nd 2016

Alessandra Ferrajoli, MD, a professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the challenges that still remain in patients with chronic lymphocytic leukemia.

Dr. Lau on Controversies Surrounding Prostate Cancer Screening

November 1st 2016

Clayton S. Lau, MD, director, Urologic Oncology, director, Robotic Surgery, Prostate Cancer Surgery, interim chair of Urology, City of Hope, discusses the controversies surrounding prostate cancer screening. Lau spoke on this in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Blackwell on the Impact of the CLEOPATRA and MARIANNE Studies in HER2+ Breast Cancer

November 1st 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the lasting impact that the CLEOPATRA and MARIANNE studies have had on the treatment landscape in HER2-positive breast cancer.

Dr. Chao on Predicting Survival Following Stereotactic Spinal Radiosurgery

November 1st 2016

Samuel Chao, MD, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, discusses spine stereotactic radiosurgery for the treatment of metastases located on the spine.

Dr. Zagaja on Major Benefit With Prostatectomy

November 1st 2016

Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.

Dr. Wierda on Frontline Management of Patients With CLL

October 31st 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the management of patients with chronic lymphocytic leukemia (CLL) in the firstline setting.

Dr. Den on Radiation Therapy in Prostate Cancer

October 31st 2016

Robert B. Den, MD, associate professor of Radiation Oncology, Jefferson Health, discusses the use of radiation therapy as a treatment for patients with prostate cancer.

Dr. Eggener on PSA-Based Screening in Early-Stage Prostate Cancer

October 31st 2016

Scott Eggener, MD, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer. Eggier shared these thoughts during the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.

Dr. Adam Dicker on Combination Treatments With Radiation Therapy

October 31st 2016

Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the potential for radiation combinations.